MRK

Merck (MRK)

Merck and Co Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:MRK
DateTimeSourceHeadlineSymbolCompany
09/29/20223:22PMBusiness WireU.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit NYSE:MRKMerck and Co Inc
09/29/20226:45AMBusiness WireMerck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27 NYSE:MRKMerck and Co Inc
09/27/20227:00AMBusiness WireMerck Animal Health Completes Minority Investment in LeeO Precision Farming NYSE:MRKMerck and Co Inc
09/27/20226:45AMBusiness WireMerck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) NYSE:MRKMerck and Co Inc
09/22/20223:42PMDow Jones NewsTrending: Merck Reports Court Win in Diabetes Patent Lawsuit Against Viatris NYSE:MRKMerck and Co Inc
09/22/20228:13AMDow Jones NewsMerck Boosts Animal-Health Line With Virtual-Fence-Firm Vence NYSE:MRKMerck and Co Inc
09/22/20227:38AMDow Jones NewsCourt Favors Merck in Diabetes Patent Lawsuit Against Viatris NYSE:MRKMerck and Co Inc
09/22/20227:30AMBusiness WireMerck Animal Health to Acquire Vence NYSE:MRKMerck and Co Inc
09/22/20226:45AMBusiness WireLYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer NYSE:MRKMerck and Co Inc
09/22/20226:40AMBusiness WireU.S. District Court Rules In Favor of Merck in Sitagliptin Phosphate Patent Lawsuit NYSE:MRKMerck and Co Inc
09/20/20229:29AMTipRanksMohamed El-Erian Says Stagflation Is Coming; Here Are 2 ‘Strong Buy’ Dividend Stocks to Protect Your Portfolio NYSE:MRKMerck and Co Inc
09/20/20227:42AMDow Jones NewsMerck to Begin New Phase 3 Trial for Islatravir HIV-1 Treatment NYSE:MRKMerck and Co Inc
09/20/20226:45AMBusiness WireMerck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection NYSE:MRKMerck and Co Inc
09/16/20227:30AMBusiness WireMerck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children NYSE:MRKMerck and Co Inc
09/13/20227:05AMPR Newswire (Canada)Health Canada Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults and Children with Stage IIB or IIC Melanoma Following Complete Resection NYSE:MRKMerck and Co Inc
09/13/20227:05AMPR Newswire (Canada)Santé Canada approuve KEYTRUDA® (pembrolizumab) comme traitement adjuvant chez les adultes et les enfants atteints d'un mélanome de stade IIB ou IIC après une résection complète NYSE:MRKMerck and Co Inc
09/12/20228:55AMPR Newswire (US)Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer NYSE:MRKMerck and Co Inc
09/12/20228:55AMBusiness WireSeagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer NYSE:MRKMerck and Co Inc
09/11/20228:55PMTipRanksMizuho Securities Keeps Their Buy Rating on Merck & Company (MRK) NYSE:MRKMerck and Co Inc
09/11/20224:15AMBusiness WireFive-Year Data for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer (NSCLC) NYSE:MRKMerck and Co Inc
09/10/20222:30AMBusiness WireMerck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma NYSE:MRKMerck and Co Inc
09/09/20229:11AMDow Jones NewsAstraZeneca, Merck Say Lynparza Trial Shows Long-Term Survival Increase NYSE:MRKMerck and Co Inc
09/09/20228:00AMBusiness WireLYNPARZA® (olaparib) in Combination With Bevacizumab, and as Monotherapy, Demonstrates Clinically Meaningful Long-Term Survival in Certain Patients With First-Line Advanced Ovarian Cancer in Exploratory Analyses of Two Phase 3 Trials NYSE:MRKMerck and Co Inc
09/08/202210:00AMBusiness WireMerck Foundation Launches $20 Million Initiative to Advance Equity in U.S. Cancer Care NYSE:MRKMerck and Co Inc
09/06/20226:45AMBusiness WireMerck to Present at the Morgan Stanley 20th Annual Global Healthcare Conference NYSE:MRKMerck and Co Inc
09/05/20227:35PMTipRanksMizuho Securities Sticks to Their Buy Rating for Merck & Company (MRK) NYSE:MRKMerck and Co Inc
08/30/20224:01PMBusiness WireMerck Reports Strong Progress in ESG Focus Areas NYSE:MRKMerck and Co Inc
08/29/20226:45AMBusiness WireMerck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer NYSE:MRKMerck and Co Inc
08/25/20226:45AMBusiness WireLYNPARZA® (olaparib) Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer NYSE:MRKMerck and Co Inc
08/23/20227:39AMDow Jones NewsMerck Gets FDA Fast-Track Designation for MK-2060 Anticoagulant Therapy NYSE:MRKMerck and Co Inc
 Showing the most relevant articles for your search:NYSE:MRK
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

Log in to ADVFN
Register Now
NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20221002 15:24:59